Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and ...

Operating profit before special items increased by 5% year-over-year. Coloplast reaffirmed its FY 2025 guidance of 8%-9% organic revenue growth and an EBIT margin of approximately 28%. The company ...

Growth in Interventional Urology was negatively impacted by a voluntary product recall in Bladder Health and Surgery (around DKK 25 million in Q1), partly offset by solid performance in Endourology.